Calithera Biosciences, Inc.

78 articles with Calithera Biosciences, Inc.

• Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

  10/3/2019

  Top-line results expected in second half of 2020

• New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

  9/29/2019

  Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition

• Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

  9/28/2019

  Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)

• Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019

  9/3/2019

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from two oncology programs have been selected for oral presentations at the European Society for Medical Oncology (ESMO) 2019 Congress to be held September 27-October 1, in Barcelona, Spain.

• 

  Clinical Catch-Up for the First Week of July

  7/8/2019

  Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
• 

  Clinical Catch-Up for June 17-21

  6/24/2019

  Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.

• Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

  6/17/2019

  Calithera Biosciences, Inc. announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma.

• Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839

  10/5/2018

  Phase 1/2 trials expected to initiate 1Q2019

• Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team

  9/18/2018

  ​Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board.

• Updated Results From Calithera Biosciences' Phase I Study of CB-839 in Combination With Paclitaxel in Patients With Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

  12/5/2017

  Based on these data, Calithera has opened a Phase 2 trial exploring the treatment combination in both first line and late line metastatic TNBC patients.

• 

  5 Biotechs With a Whopping 80%+ Buy Rating for Brokers

  12/5/2017

  In an overall good year for pharma and biotech sectors, there have been some standouts.

• Calithera Biosciences' Initial Results From Phase II Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting

  11/7/2017

  CB-839 is an orally bioavailable glutaminase inhibitor currently in Phase 2 trials, and Opdivo® is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression.

• Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights

  11/2/2017

  Calithera will webcast clinical update on CB-839 on November 11, 2017.

• Calithera Announces First Patient Treated in Phase I Cohort of INCB01158 Dosed in Combination With Keytruda

  10/19/2017

  The Phase 1 trial is designed to evaluate the safety and recommended Phase 2 dose of INCB01158 as a monotherapy, and in combination with immune checkpoint therapy.

• Calithera Biosciences Announces Appointment Of Sumita Ray As General Counsel

  10/3/2017

• Calithera Biosciences Appoints Blake Wise To Board Of Directors

  9/22/2017

• Calithera Biosciences Reports Second Quarter 2017 Financial Results And Recent Highlights

  8/9/2017

• Calithera Biosciences Initiates A Randomized Phase II Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma

  8/7/2017

• Calithera Biosciences To Report Second Quarter 2017 Financial Results On Tuesday, August 8, 2017

  8/2/2017

• Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma

  6/7/2017